What is Spark Therapeutics' stock symbol?
Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."
Where is Spark Therapeutics' stock going? Where will Spark Therapeutics' stock price be in 2017?
13 equities research analysts have issued 12-month price targets for Spark Therapeutics' shares. Their predictions range from $28.00 to $94.00. On average, they expect Spark Therapeutics' share price to reach $64.50 in the next year.
When will Spark Therapeutics announce their earnings?
Spark Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.
What are analysts saying about Spark Therapeutics stock?
Here are some recent quotes from research analysts about Spark Therapeutics stock:
Cantor Fitzgerald analysts commented, "2017 – Year of First Gene Therapy Approval in U.S.? Management reiterated its confidence in filing its rolling BLA in early 2017, and highlighted that the company has completed the necessary manufacturing runs to support its submission. Outstanding items for the filing include finalization of stability testing and CMC module write-up. We believe the timing of the filing could lead to the first approved gene therapy in the U.S. this year and remind investors that the FDA previously amended its granted orphan designation for voretigene neparvovec to cover inherited retinal diseases caused by biallelic RPE65 mutations." (2/23/2017)
- Stifel Nicolaus analysts commented, "Management's 4Q16 earnings announcement/call contained minimally-incremental insight on many of the data catalysts still anticipated for 1H17. We believe management's commentary around the current state of pre-commercialization activities for voretigene neparvovec (VN) ' including directionally positive feedback on both the access and reimbursement fronts ' should ameliorate some of the near-term concerns of those investors anticipating pricing/reimbursement to potentially represent a source of headline risk. We believe anticipation around a number of key near-term data catalysts ' including early-FY17 SPK-7001 data in choroideremia, updated early-April SPK-9001 data in hemophilia B, and preliminary mid-FY17 SPK-8011 data ' should keep ONCE shares at the forefront of relevancy over the coming months. Estimates largely unchanged." (2/23/2017)
According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (1/14/2017)
Who owns Spark Therapeutics stock?
Spark Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Federated Investors Inc. PA (4.46%), State Street Corp (2.93%), Janus Capital Management LLC (1.23%), Bain Capital Public Equity Management LLC (1.07%) and Deerfield Management Co. (0.92%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High, Stephen W Webster and Steven Altschuler.
Who sold Spark Therapeutics stock? Who is selling Spark Therapeutics stock?
Spark Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Deerfield Management Co., Bain Capital Public Equity Management LLC, Janus Capital Management LLC and AQR Capital Management LLC. Company insiders that have sold Spark Therapeutics stock in the last year include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High and Stephen W Webster.
Who bought Spark Therapeutics stock? Who is buying Spark Therapeutics stock?
Spark Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Highland Capital Management LP, State Street Corp, Marshall Wace LLP, Guggenheim Capital LLC, FMR LLC, Russell Investments Group Ltd., Pacad Investment Ltd. and Fred Alger Management Inc..
How do I buy Spark Therapeutics stock?
Shares of Spark Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Spark Therapeutics stock cost?
One share of Spark Therapeutics stock can currently be purchased for approximately $59.94.